36
Case study: Clario
The missing multiple
37
From merger to market leader Case Study highlight – Clario
From legacy brands to a unified growth platform.
Clario was formed through the merger of ERT and Bioclinica – two established, respected brands in clinical trial technology. Both had strong heritage, loyal customer bases and deep capabilities. The leadership team had a bold ambition: to create a new, integrated, technology-led, scientific expert partner for clinical trials. But the external perceptions and internal reality was holding this back. • Customers defaulting to legacy loyalties rather than embrace an integrated proposition • Talent remaining emotionally anchored to “ERT” or “Bioclinica” rather than commit to a new future • The market viewing the merger as consolidation, not transformation • Growth ambitions being diluted by market confusion What was at risk Without a clear, compelling unifying story:
As one leader reflected: “If we’d just changed the identity and the name without changing the culture, it would have failed.” This wasn’t about cosmetics. It was about credibility and commerciality. The decisive shift Rather than absorb one brand into the other, or maintain a house of legacy brands, together with Brandpie the decision was made to draw a clear line under the history and create a new brand, a new narrative and send a new signal to the market. Clario was positioned not as a merger of two companies, but as a forward- looking platform built for the future of clinical research. The work focused on: • Clarifying the strategic ambition • Aligning leadership around a unified story • Defining what truly differentiated the combined capability • Signalling meaningful change, internally and externally
The new brand positioning “Power of Certainty" elevated customer value and became the visible expression of a deeper transformation already underway: innovation in products, process improvements, commercial focus and cultural integration. As one executive described it, the brand acted as a “force multiplier.” It didn’t replace operational change, it amplified it. • A unified platform positioned for scale • Internal alignment across previously separate organizations • Clear market positioning as a global clinical trial technology leader • Increased confidence from customers, talent and investors • Successful integration of two complex businesses under a single entity The value unlocked The result was more than visual coherence.
Since the merger Clario has successfully grown to become the leading provider of endpoint data solutions for clinical trials, and in 2025 was acquired by Thermo Fisher Scientific, the world leader in serving science, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven for: $ 9.4 bn
Made with FlippingBook interactive PDF creator